Characterization of siderophore-mediated iron transport in Geotrichum candidum, a non-siderophore producer

Overview of a surface-ripened cheese community functioning by meta-omics analyses

Cheese ripening is a complex biochemical process driven by microbial communities composed of both eukaryotes and prokaryotes. Surface-ripened cheeses are widely consumed all over the world and are appreciated for their characteristic flavor. Microbial community composition has been studied for a long time on surface-ripened cheeses, but only limited knowledge has been acquired about its in situ metabolic activities. We applied metagenomic, metatranscriptomic and biochemical analyses to an experimental surface-ripened cheese composed of nine microbial species during four weeks of ripening. By combining all of the data, we were able to obtain an overview of the cheese maturation process and to better understand the metabolic activities of the different community members and their possible interactions. Furthermore, differential expression analysis was used to select a set of biomarker genes, providing a valuable tool that can be used to monitor the cheese-making process.

How way leads on to way

In this article, I briefly recount the historical events in my native country that led me to become a plant pathologist. I started as a field pathologist specializing in fungal diseases of legumes, moved to biochemical research on virulence factors, and then on to molecular plant-microbe interactions. I describe the impact my graduate studies at the University of California (UC)-Davis had on my career. My life's work and teaching can be said to reflect the development in plant pathology during the past 40 years. I have included a concise review of the development of plant pathology in Israel and the ways it is funded. Dealing with administrative duties while conducting research has contributed to my belief in the importance of multidisciplinary approaches and of preserving the applied approach in the teaching of plant pathology.

Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus

Mucormycosis caused by the fungus Rhizopus has been documented in iron overloaded patients and more particularly in dialysis patients, both when treated with desferrioxamine B (DFO). This iron and aluminium chelator is thought to play a role in the pathogenesis of this infection. We therefore investigated in vitro the cellular pharmacology of iron chelated by DFO in the fungus Rhizopus. In a medium, designed for fungal cultivation, Rhizopus microsporus var. rhizopodiformis takes up iron from ferric-DFO complex (55Fe.DFO) and from 55Fe.rhizoferrin, the siderophore synthesized and secreted by Rhizopus [Drechsel et al., Biol. Metals 4: 238-243, 1991]. In both cases, iron accumulation is partially saturable with the duration of exposure and the chelator concentration. Fe.DFO binds to Rhizopus; iron becomes trapped and remains associated with the fungus, whereas the iron-depleted siderophore is released in the extracellular medium. In a medium designed for mammalian cell cultivation and in the absence of human serum, the fungal iron accumulation both from 55Fe.DFO and from 55Fe.rhizoferrin is proportional to the chelator concentration. Human serum at 40% does not influence the iron accumulation from Fe.DFO but it significantly affects that from Fe.rhizoferrin which, in the presence of serum, only occurs at concentration > 5 microM. This difference finds its explanation in the iron transfer observed between Fe.rhizoferrin and seric apotransferrin, the latter making the metal unavailable to Rhizopus. By contrast, no iron transfer takes place between Fe.DFO and apotransferrin, allowing fungal iron utilization from this complex, even at very low concentrations. The iron uptake, being inhibited by NaN3 and KCN, is energy-dependent; being inhibited by bipyridyl, it requires prior reduction of ferric iron; being unaffected by the covalent linkage of Fe.DFO to albumin, it does not require the entry of Fe.DFO within the fungus. These in vitro results strongly suggest that, upon administration of DFO to iron overloaded or dialysis patients, the formed Fe.DFO is efficiently used as an iron source by Rhizopus, even in the presence of serum apotransferrin or rhizoferrin. The consequent promotion of the growth of Rhizopus helps explain the increased risk of mucormycosis in DFO-treated patients.

Mucormycosis during deferoxamine therapy is a siderophore-mediated infection. In vitro and in vivo animal studies

This study investigates the pathophysiology of mucormycosis caused by Rhizopus, which has been reported in 46 dialysis patients, while treated with deferoxamine (DFO). This drug aggravates mucormycosis, which we experimentally induced in guinea pigs and which lead to a shortened animal survival (P < or = 0.01). The drug's effect on Rhizopus is not mediated through the polymorphonuclear cells. Fe.DFO, the iron chelate of DFO, abolishes the fungistatic effect of serum on Rhizopus and increases the in vitro growth of the fungus (P < or = 0.0001). This effect is present at Fe.DFO concentrations > or = 0.01 microM, at which fungal uptake of radioiron from 55Fe.DFO is observed. A 1,000-fold higher concentration of iron citrate is required to achieve a similar rate of radioiron uptake and of in vitro growth stimulation as observed with Fe.DFO. These in vitro effects of Fe.DFO (1 microM) in serum on radioiron uptake and on growth stimulation are more striking for Rhizopus than for Aspergillus fumigatus and are practically absent for Candida albicans. For these three fungal species, the rates of radioiron uptake from 55Fe.DFO and of growth stimulation in the presence of Fe.DFO in serum are directly related (r = 0.886). These results underscore the major role of Fe.DFO in the pathogenesis of DFO-related mucormycosis. Pharmacokinetic changes in uremia lead to a prolonged accumulation of Fe.DFO after DFO administration, which helps explain the increased sensitivity of dialysis patients to DFO-related mucormycosis.